An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours

European Journal of Cancer

Volumn 47, Issue 11, 2011, Pages 1736-1746

  Kelly, Rebecca K ^a   Olson, Dian L ^a   Sun, Yaping ^a   Wen, Dingyi ^a   Wortham, Kathleen A ^a   Antognetti, Giovanna ^a   Cheung, Anne E ^a   Orozco, Olivia E ^a   Yang, Lu ^a   Bailly, Veronique ^a   Sanicola, Michele ^a  

^a BIOGEN   (United States)

Author keywords

Antibody cytotoxic conjugate; Cripto; Payload; Targeted therapeutic

Indexed keywords

ANTIBODY CONJUGATE; BIIB 015; CRIPTO PROTEIN; CYTOTOXIC AGENT; FLUOROURACIL; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TESTIS TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, SCID; MODELS, CHEMICAL; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS;

EID: 79959947572     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.023     Document Type: Article

References (38)

1. C. Bianco, L. Strizzi, and N. Normanno Cripto-1: an oncofetal gene with many faces Curr Top Dev Biol 67 2005 85 133 (Pubitemid 43631284)
2. C. Sun, O. Orozco, and D.L. Olson CRIPTO3, a presumed pseudogene, is expressed in cancer Biochem Biophys Res Commun 377 2008 215 220
3. C.Y. Yeo, and M. Whitman Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms Mol Cell 7 2001 949 957 (Pubitemid 32525742)
4. L. Strizzi, C. Bianco, and N. Normanno Cripto-1: A multifunctional modulator during embryogenesis and oncogenesis Oncogene 24 2005 5731 5741 (Pubitemid 43086133)
5. R.V. Chari Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc Chem Res 41 2008 98 107
6. J. Brennan, C.C. Lu, and D.P. Norris Nodal signalling in the epiblast patterns the early mouse embryo Nature 411 2001 965 969 (Pubitemid 32601495)
7. C.C. Lu, and E.J. Robertson Multiple roles for Nodal in the epiblast of the mouse embryo in the establishment of anterior-posterior patterning Dev Biol 273 2004 149 159 (Pubitemid 39078373)
8. N.J. Kenney, H.B. Adkins, and M. Sanicola Nodal and Cripto-1: Embryonic pattern formation genes involved in mammary gland development and tumorigenesis J Mammary Gland Biol Neoplasia 9 2004 133 144 (Review) (Pubitemid 39177499)
9. F. Ciardiello, R. Dono, N. Kim, M.G. Persico, and D.S. Salomon Expression of Cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line Cancer Res 51 1991 1051 1054
10. H.B. Adkins, C. Bianco, and S.G. Schiffer Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo J Clin Invest 112 2003 575 587 (Pubitemid 38056342)
11. P.C. Gray, C.A. Harrison, and W. Vale Cripto forms a complex with activin and type II activin receptors and can block activin signalling Proc Natl Acad Sci USA 100 2003 5193 5198 (Pubitemid 36542681)
12. J.A. Kelber, G. Shani, E.C. Booker, W.W. Vale, and P.C. Gray Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal J Biol Chem 283 2008 4490 4500
13. C. Wechselberger, L. Strizzi, and N. Kenney Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma Oncogene 24 2005 4094 4105 (Pubitemid 40897055)
14. C. Wechselberger, A.D. Ebert, and C. Bianco Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells Exp Cell Res 266 2001 95 105 (Pubitemid 32989046)
15. Y.P. Gong, P.M. Yarrow, and H.L. Carmalt Overexpression of Cripto and its prognostic significance in breast cancer: A study with long-term survival Eur J Surg Oncol 33 2007 438 443 (Pubitemid 46586094)
16. A. D'Antonio, S. Losito, and S. Pignata Transforming growth factor alpha, amphiregulin and Cripto-1 are frequently expressed in advanced human ovarian carcinomas Int J Oncol 21 2002 941 948
17. D. Ertoy, A. Ayhan, and E. Sarac Clinicopathological implication of Cripto expression in early stage invasive cervical carcinomas Eur J Cancer 36 2000 1002 1007 (Pubitemid 30316425)
18. J.M. Topczewska, L.M. Postovit, and N.V. Margaryan Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness Nat Med 12 2006 925 932 (Pubitemid 44175144)
19. L.M. Postovit, N.V. Margaryan, and E.A. Seftor Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells Proc Natl Acad Sci USA 105 2008 4329 4334 (Pubitemid 351754380)
20. L. Strizzi, D.E. Abbott, and D.S. Salomon Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma Cell Cycle 7 2008 1931 1935 (Pubitemid 352030336)
21. B.F. Issell, and S.T. Crooke Maytansine Cancer Treat Rev 5 1978 199 207 (Pubitemid 9109517)
22. C. Liu, B.M. Tadayoni, and L.A. Bourret Eradication of large colon tumor xenografts by targeted delivery of maytansinoids Proc Natl Acad Sci USA 93 1996 8618 8623 (Pubitemid 26269609)
23. P.J. Carter, and P.D. Senter Antibody-drug conjugates for cancer therapy Cancer J 14 2008 154 169 (Review)
24. A.M. Wu, and P.D. Senter Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23 2005 1137 1146 (Review) (Pubitemid 41486395)
25. I.E. Krop, M. Beeram, and S. Modi Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer Clin Oncol 28 2010 2698 2704
26. I. Niculescu-Duvaz Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer Curr Opin Mol Ther 12 2010 350 360
27. H.A. Burris III, H.S. Rugo, and S.J. Vukelja Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) - positive breast cancer after prior HER2-directed therapy JCO 2011 398 405
28. A. Younes, N.L. Bartlett, and J.P. Leonard Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 2010 1812 1821
29. S.C. Alley, N.M. Okeley, and P.D. Senter Antibody-drug conjugates: targeted drug delivery for cancer Curr Opin Chem Biol 14 2010 529 537
30. G.D. Lewis Phillips, G. Li, and D.L. Dugger Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 2008 9280 9290
31. A.W. Tolcher, L. Ochoa, and L.A. Hammond Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study J Clin Oncol 21 2003 211 222 (Pubitemid 46606149)
32. R.T. Eagan, J.N. Ingle, J. Rubin, S. Frytak, and C.G. Moertel Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication J Natl Cancer Inst 60 1978 93 96 (Pubitemid 8287174)
33. H.K. Erickson, P.U. Park, and W.C. Widdison Antibody-Maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res 66 2006 4426 4433
34. S.G. Schiffer, and A. Foley SKaffashan Fucosylation of Cripto is required for its ability to facilitate nodal signaling J Biol Chem 276 2001 37769 37778
35. S.C. Alley, D.R. Benjamin, and S.C. Jeffrey Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjug Chem 19 2008 759 765 (Pubitemid 351431408)
36. J. Rodon, M. Garrison, and L.A. Hammond Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study Cancer Chemother Pharmacol 62 2008 911 919
37. H.K. Erickson, W.C. Widdison, and M.F. Mayo Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug Chem 21 2010 84 92
38. N.M. Okeley, J.B. Miyamoto, and X. Zhang Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate Clin Cancer Res 16 2010 888 897